Clinical trial
Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With…
NCT01575834 · Amgen, Industry · Completed
Key facts
| NCT number | NCT01575834 |
|---|---|
| Title | Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis |
| Official title | A Multicenter, International, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis |
| Acronym | FRAME |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Postmenopausal Osteoporosis |
| Intervention type | Drug |
| Interventions | Romosozumab, Placebo, Denosumab |
| Enrollment | 7,180 |
| Start date | Mar 15, 2012 |
| Primary completion | Dec 14, 2015 |
| Completion | Dec 28, 2016 |
| First posted | Apr 12, 2012 |
| Last update posted | Aug 28, 2024 |
| Countries | Argentina, Australia, Belgium, Brazil, Canada, Colombia, Czechia, Denmark, Dominican Republic, Estonia, Germany, Hungary and 12 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: